Finolizumab

Phase 2Monoclonal antibody

EEye & ENT Hospital of Fudan University

Finolizumab is one of 14 small molecule programs targeting Hypopharyngeal Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hypopharyngeal CarcinomaActive, not recruiting

Hypopharyngeal CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

16 competitors in Hypopharyngeal Carcinoma

#DrugCompanyPhaseTrials

Taxol

Adrucil

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

3 4

Taxotere

AAvyxa

Phase 3

2 5

Platinum

Bristol-Myers Squibb

Phase 3

1 6

Neoadjuvant Chemotherapy

JJapan Clinical Oncology Group

Phase 3

1 7

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

2 8

Tuoyi

SSun Yat-sen University

Phase 2

1 9

Tuoyi

CCoherus Oncology, Inc.

Phase 2

1 10

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 2

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 2Recruiting

Hypopharyngeal Carcinoma

NCT07248956

Clinical

Trials by Indication[1]

Hypopharyngeal Carcinoma1 trial

Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma

Recruiting·EEye & ENT Hospital of Fudan University·Phase 2·NCT07248956·116 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Finolizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Finolizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Finolizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eye & ENT Hospital of Fudan University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: EEye & ENT Hospital of Fudan University

Finolizumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Hypopharyngeal Carcinoma1 trial

References

Drug Info

Quick Facts

Related News